3597 - Dosimetric Evaluation of Organs-at-Risk and Quality of Life Assessment between Standard of Care and Dose De-Escalated Radiation in HPV Positive Oropharyngeal Cancer
Location: Hall C
Presenter: Amy Abdalla, MD – University of Missouri - Ellis Fischel Cancer Center
10:30 AM - 11:45 AM ET
3598 - Early Recurrence in Patients Treated with Surgical Resection and Postoperative Radiotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
3603 - The Use of a Low Dose Elective Volume in Head and Neck Stereotactic Body Radiation Therapy (SBRT): Initial Report of Outcomes of a Novel Planning Approach
3605 - "Big Jolts Like an Electric Shock:" Patient Perspectives on the Expectations, Experiences and Quality-of-Life Impact of Androgen Deprivation Therapy (ADT) for Prostate Cancer
3607 - Independent Review Organization and Proton Therapy: Multi-State Analysis and Legal Procedural Strategies
Location: Hall C
Presenter: Etzer Augustin, MD, MS – UF Health Radiation Oncology – Davis Cancer Pavilion
10:30 AM - 11:45 AM ET
3608 - The Impact of Circulating Tumor Human Papillomavirus (HPV) DNA Clearance Kinetics on Disease Outcomes during Chemoradiation in Patients with HPV-Associated Oropharyngeal Cancer
3609 - FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab + Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Location: Hall C
Presenter: Julie Bauman, MD – George Washington University Cancer Center
10:30 AM - 11:45 AM ET
3610 - The Role of Mouthguard Customization to Minimize Risk of Radiation Backscatter in Head and Neck Cancer Patients
3611 - A Pilot, First in Human Study of Autologous IFN-Gamma Stimulated Mesenchymal Stromal Cells for Treatment of Radiation-Induced Xerostomia - Results of Contralateral Injections
3618 - Region and Language Centric, Virtual Education and Training in Latin America: Stereotactic Body Radiotherapy and Radiosurgery Curriculum in Spanish for Medical Physicists and Radiation Oncologists
3623 - Prognostic Significance of Dynamics in Pan-Immune-Inflammation Value in Patients with Head and Neck Cancer Treated with Radiotherapy: Results from a Large Cohort Study
3624 - The Correlation Study of Circadian Clock Gene Bmal1 on Growth Inhibition and Radiosensitivity in Subcutaneous Xenograft of Human Nasopharyngeal Carcinoma CNE1 in Nude Mice
Location: Hall C
Presenter: Yue Chen, MS, MBBS – The Affiliated Cancer Hospital of Guizhou Medical University
10:30 AM - 11:45 AM ET
3625 - Massive Nasal Bleeding in Patients with Nasopharyngeal Carcinoma Received Curative Radiotherapy
3627 - Safety and Activity Profile of Fianlimab (Anti-LAG-3) in Combination With Cemiplimab (Anti-PD-1) and Cemiplimab Monotherapy in Recurrent and/or Metastatic HNSCC
3629 - Long-Term Results of External Beam Radiation Therapy (RT) with or without Concurrent Chemotherapy in Loco-Regionally Advanced or Recurrent Differentiated Thyroid Cancer (DTC)
3635 - Nasopharynx Cancer in the U.S.: Disparities in Stage at Presentation
Location: Hall C
Presenter: Edward Dee, MD – Memorial Sloan Kettering Cancer Center
10:30 AM - 11:45 AM ET
3636 - Nasopharynx Cancer in Southeast Asia: An Analysis of 2022 Incidence and Mortality
Location: Hall C
Presenter: Edward Dee, MD – Memorial Sloan Kettering Cancer Center
10:30 AM - 11:45 AM ET
3637 - HPV-DNA Titers and Tumor Volume Correlation in Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Location: Hall C
Presenter: Ahmed Ghanem, MD, PhD – Henry Ford Cancer Institute/Alexandria University
10:30 AM - 11:45 AM ET
3638 - Individualized Thyroid Prescriptions Based on a Novel Tolerance Dose Model for Radiation-Induced Hypothyroidism in Nasopharyngeal Carcinoma Patients
3648 - Osteoradionecrosis Incidence in Oral Cavity Squamous Cell Carcinoma
Location: Hall C
Presenter: Alyssa Farley, MD – University of Cincinnati - Barrett Cancer Center
10:30 AM - 11:45 AM ET
3649 - Understanding Current Processes of Multidisciplinary Collaboration in Radiation Oncology Treatment Planning and Follow-Up across NCORP Network Practices
3651 - Clinical and Dosimetric Factors Associated with Reactive Gastrostomy Tube Placement in Patients Treated with Radiotherapy for Head and Neck Cancer
3654 - Multicenter Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Secondary Analysis of Association of Lymphopenia with Treatment Modality, Emer
3656 - Clinical Outcomes after Dose De-Escalation for Prophylactic Nodal Irradiation in Nasopharyngeal Carcinoma: A Long-Term, Single-Center Experience
3658 - Dosimetric Predictors of Hypothyroidism after Combined Modality Therapy ± Immunotherapy for HPV-Related Oropharyngeal Cancer: A Secondary Analysis of Prospective Trials
3659 - Examining Rectal Spacer Use in Prostate Cancer Radiation Therapy by Treatment Modality: Insights from Medicare Claims Data
Location: Hall C
Presenter: Ryan Hankins, MD – Medstar Georgetown University Hospital
10:30 AM - 11:45 AM ET
3660 - Evaluation of Adjuvant Chemotherapy after Induction Chemotherapy and Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Propensity Score-Matched Analysis
3662 - Multi-Sequence MRI Based Metachronous Single-Organ Metastasis Prediction of Nasopharyngeal Carcinoma
Location: Hall C
Presenter: Peng Zhang, MD – Sichuan Cancer Hospital and Institute
10:30 AM - 11:45 AM ET
3663 - Predicting the Risk of Local Failure after Treatment for Head and Neck Squamous Cell Carcinoma Using Clinical and Post-Radiotherapy PET/CT Imaging Features
Location: Hall C
Presenter: Ryan Hughes, MD – Wake Forest University School of Medicine
10:30 AM - 11:45 AM ET
3664 - Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Location: Hall C
Presenter: Zain Husain, MD – Southern California Permanente Medical Group
10:30 AM - 11:45 AM ET
3665 - Impact of Depth of Invasion on Locoregional Failure in RTOG 0920-Eligible Early-Stage Oral Tongue Squamous Cell Carcinoma and Implications for Adjuvant Therapy
3666 - Global Disparities in Current Clinical Trials in Nasopharyngeal Carcinoma
Location: Hall C
Presenter: Carl Jay Jainar, MD – University of Santo Tomas Hospital, Benavides Cancer Institute
10:30 AM - 11:45 AM ET
3667 - Effect of Time-of-Day Nivolumab and Stereotactic Body Radiotherapy in Metastatic Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Prospective Randomized Trial
3670 - The Geriatric 8 Score is Associated with Determination of Treatment Strategy and Survival Outcomes for Curative Radiotherapy of Head and Neck Cancer in the Elderly
3678 - Preliminary Evaluation of HyperArc Stereotactic Body Radiotherapy for Local Recurrent Nasopharyngeal Cancer: Do Dosimetric Advantages Translate into Therapeutic Benefits?
3681 - Long Term Outcomes And Late Toxicity of Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting Radiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized,
3682 - Compare the Predictive Performance of Deep Learning and Radiomics Models for Predicting Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma
3685 - Association of Weekly Cisplatin vs. Carboplatin and Paclitaxel with Outcomes among Patients with Head and Neck Cancer Treated with Definitive Chemoradiation
Location: Hall C
Presenter: Sung Jun Ma, MD – The James Cancer Hospital & Solove Research Institute
10:30 AM - 11:45 AM ET
3686 - Association of the Number of Weekly Cisplatin Cycles with Outcomes among Patients with Head and Neck Cancer Treated with Definitive Chemoradiation
Location: Hall C
Presenter: Sung Jun Ma, MD – The James Cancer Hospital & Solove Research Institute
10:30 AM - 11:45 AM ET
3687 - Patterns of Palliative Radiotherapy Use in Botswana
3691 - Trial in Progress: CTEP 10492, A Phase 1/1b Study of the AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinoma
3692 - Treatment Outcome Priorities for Patients with Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC) before and 12 Months after Primary (Chemo)Radiation (CRT/RT): Results from a Prospective Lo
3693 - Sexual Health, Facial Appearance and Appearance Distress in Patients with Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC) Patients Undergoing (Chemo)Radiation (CRT/RT): Final Results fro
3698 - Relationship between Elective Neck Irradiation and Severe Lymphopenia in Patients Treated with Head and Neck Chemoradiotherapy
Location: Hall C
Presenter: Townes Mickel, MD – University of Texas Southwestern Medical Center
10:30 AM - 11:45 AM ET
3699 - Dosimetric Results for Organs at Risk (OAR) from Radiotherapy Dose De-Escalation to the Subclinical Region in HPV-Mediated Oropharyngeal Cancer (HPV+ OPC): A Retrospective Analysis
3702 - NCDB Analysis of Low-Risk HPV-Related H&N SCC of the Oropharynx Treated with Surgery: Can Adjuvant RT be Safely Omitted in Node Positive Patients?
3709 - Evaluation of Nasopharyngeal Carcinoma Clinical Target Volume Automatic Delineation Based on Recurrence Regions in Radiotherapy
Location: Hall C
Presenter: Xiaomin Ou, MD – Fudan University Shanghai Cancer Center
10:30 AM - 11:45 AM ET
3710 - Cesium-131 Brachytherapy in Patients that are Not Candidates for Post-Operative External Beam Radiation Therapy: Interim Results of a Single Arm Prospective Study
3714 - Analysis of Avasopasem Manganese on Swallowing Outcomes for Oropharynx and Oral Cavity Patients Following Chemoradiation - A Single Institution Report
3715 - The Impact of Age and Tumor Volume on Volumetric Systemic Therapy Response in HPV-Positive Oropharyngeal HNSCC - A Pooled Analysis of Prospective Trials
3716 - Long Term Dysphagia Outcomes in Patients of Post Operative Oral Cavity Cancers Treated with Adjuvant Dysphagia Optimized vs. Standard Intensity Modulated Radiotherapy
3724 - Safe Deviation from the "5+5" Expansion Rule for the Delineation of Primary Tumor Clinical Target Volume (CTV-P) in Oropharyngeal Cancer: A Prospective Cohort Study
3725 - Global Interobserver Variations of Clinical Target Volume (CTV) Delineation among International Experts in Predefined Gross Tumor Volume (GTV) and Organs at Risk (OAR) Volumes in Head and Neck Cancer
3726 - Global Interobserver Variations of Clinical Target Volume (CTV) Delineation among International Experts in Given Standard Gross Tumor Volume (GTV) and Organs at Risk (OAR) Volumes in Lung Cancer
3727 - Global Interobserver Variations of Prescription and Plan Evaluation within Heterogeneous Clinical Target Volume (CTV) Delineations among International Experts in Head and Neck Cancers
3729 - Impact of Titanium Plate Reconstruction and Dental Amalgam on Risk of Osteoradionecrosis in Oral Cavity Cancer Patients Receiving Intensity Modulated Radiation Therapy
3733 - Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Location: Hall C
Presenter: sun shiran, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences
10:30 AM - 11:45 AM ET
3734 - Long-Term Treatment Outcomes and Late Toxicity between Childhood and Adult Nasopharyngeal Carcinoma in the Era of IMRT
Location: Hall C
Presenter: sun shiran, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences
10:30 AM - 11:45 AM ET
3735 - Kidney Cancer Patients Treatment Preferences for Localized Disease
3736 - Comparative Study to Assess the Quality of Life in Patients with Oral Cavity Cancer Treated with Adjuvant Radiation Therapy: Standard Intensity Modulated Radiotherapy vs. Dysphagia Optimized Intensity
3737 - Implications of the Primary Site and Additional Clinical Target Volume Margin in Target Volume Delineation for Intensity Modulated Radiation Therapy with Moderate Hypofractionation in Head Neck Cancer
3742 - Boosting Antiproliferative Outcomes in Oral Cancer via Combined X-Ray and 6-n-butoxy-10-nitro-12,13-dioxa-11-azatricyclo[7.3.1.02,7]trideca-2,4,6,10-tetraene Therapy
3748 - Long-Term Tumor Outcomes in Patients with Head and Neck Cancer Treated with Avasopasem Manganese to Mitigate Severe Oral Mucositis: A Single Institution Retrospective Analysis
3749 - Oral Squamous Cell Carcinoma Patients with Positive Cervical Nodes and Extracapsular Extension: A Real-World Data
Location: Hall C
Presenter: Rohit Vadgaonkar, MD – Homi Bhabha Cancer Hospital and Research Centre
10:30 AM - 11:45 AM ET
3750 - Advancing Image-Based Assessment of Long-Term Parotid-Gland Toxicity in Head and Neck Cancer Radiotherapy: Ultrasound Radiomics and Machine Learning
Location: Hall C
Presenter: Tian Liu, PhD – Icahn School of Medicine at Mount Sinai
10:30 AM - 11:45 AM ET
3751 - Radiotherapy in Addition to Immunotherapy-Based Systemic Therapy Delays Progression and Prolongs Survival in Recurrent Head and Neck Cancer
Location: Hall C
Presenter: Jingbo Wang, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences
10:30 AM - 11:45 AM ET
3752 - The Efficacy of PD-1 Inhibitor and Induction Chemotherapy Followed by Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinomas
Location: Hall C
Presenter: Jingbo Wang, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences
10:30 AM - 11:45 AM ET
3753 - Deep Transfer Learning and Dosiomics for Predicting Radiation-Induced Temporal Lobe Injury in Nasopharyngeal Carcinoma
Location: Hall C
Presenter: Li Wang, MD, PhD, MS – Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research
10:30 AM - 11:45 AM ET
3754 - Proton Therapy for Oral Cavity Cancers: A Dosimetric Comparison of Patients Enrolled on Trial of Hypofractionation
3755 - Incidence and Outcome of Non-Malignant Pharyngeal Ulceration Following Definitive (Chemo)Radiation in Oropharyngeal Squamous Cell Carcinoma (SCC)
3756 - Emergency Room (ER) Utilization Rate Among Patients with HPV related Oropharynx Cancer Undergoing Radiation De- Escalation
Location: Hall C
Presenter: Yingzhi Wu, MSN – Memorial Sloan Kettering Cancer Center
10:30 AM - 11:45 AM ET
3757 - Individualized CTV Delineation Method for Nasopharyngeal Carcinoma Based on Safe Distance Expansion from Primary Tumor: A Preliminary Efficacy Report from a Prospective Observational Study
3758 - Efficacy of Postoperative Radiotherapy Following Induction Immunochemotherapy and Surgical Resection in Locally Advanced Head and Neck Squamous Cell Carcinoma
Location: Hall C
Presenter: Yi Xu, MD – National Cancer Center CAMS & PUMC
10:30 AM - 11:45 AM ET
3759 - MRI-Based Quantification of Intratumoral Heterogeneity in Locally Advanced Nasopharyngeal Carcinoma
Location: Hall C
Presenter: Ge Yan, MD, PhD – Shanghai General Hospital, Shanghai Jiaotong University
10:30 AM - 11:45 AM ET
3760 - Anatomical and Dosimetric Variations during VMAT in Patients with Locally Advanced Nasopharyngeal Carcinoma after Induction Therapy: Implications for Adaptive Radiation Therapy
Location: Hall C
Presenter: Kunyu Yang, MD, DSc, PhD – Union Hospital Cancer Center, Tongji Medical College, HUST
10:30 AM - 11:45 AM ET
3761 - Optimal Target-Specific PTV Margins for Nasopharyngeal Carcinoma Radiotherapy with Daily FBCT Guidance
Location: Hall C
Presenter: Yu-Xian Yang, MD – Sun Yat-Sen University Cancer Center
10:30 AM - 11:45 AM ET
3762 - Taste Changes in Patients Receiving Head and Neck Radiation - Initial Analysis from a Prospective Study
3765 - Multimodal Magnetic Resonance-Based Clinicoradiomics for Predicting Suspicious Lymph Node Metastasis in Nasopharyngeal Carcinoma
Location: Hall C
Presenter: Jun Yin, MD – Sichuan Cancer Hospital and Institute
10:30 AM - 11:45 AM ET
3766 - Proton Therapy for Head/Neck Adenoid Cystic Carcinoma (ACC)
Location: Hall C
Presenter: Irini Youssef, MD – Memorial Sloan Kettering Cancer Center
10:30 AM - 11:45 AM ET
3767 - Evaluation of the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 (ESMO-MCBS v.1.1) for the Treatment of Extracranial Oligometastatic Non-Small Cell Lung Cancer with Radiosurgery
3769 - Exploring the Role of Serum Uric Acid as a Potential Biomarker in Nasopharyngeal Carcinoma: A Retrospective Study Post-Adjuvant Chemotherapy
Location: Hall C
Presenter: Lei Zeng, MD – The Second Affiliated Hospital of Nanchang University
10:30 AM - 11:45 AM ET
3770 - Theoretical Research on Temporal Lobe Injury after Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma Using Machine Learning Approach and its Clinical Application
Location: Hall C
Presenter: Lei Zeng, MD – The Second Affiliated Hospital of Nanchang University
10:30 AM - 11:45 AM ET
3771 - The Efficacy and Safety Profile of PRaG "Therapy" in Geriatric Patients with Advanced Refractory Solid Malignant Tumors
Location: Hall C
Presenter: Xiangrong Zhao, MS – The Second Affiliated Hospital of Soochow University
10:30 AM - 11:45 AM ET
3772 - Dosimetric Benefit of Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma